Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (EVGN) reported a third-quarter net loss of $2.862 million for 2026, versus net income of $5.197 million a year earlier. Quarterly revenue fell to $141,000 from $312,000 after the Bayer collaboration ended in May 2026. For the first nine months, revenue fell to $822,000 from $3.189 million and the net loss widened to $10.525 million from $2.473 million. Cash, cash equivalents and short-term bank deposits totaled approximately $9.2 million at September 30, 2026.
Evogene is refining drug candidates for acute graft-versus-host disease ahead of studies to support an application for human testing. Its AgPlenus subsidiary identified compounds active against fungicide-resistant Septoria strains. In plant tissue tests, selected compounds reduced Septoria disease severity by up to 75% versus untreated controls.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Drug candidate refinement is underway to select molecules and advance toward studies supporting an application for human testing.
- Minor pointLoss per share from continuing operations narrowed to $0.17 from $0.27 in Q3 and to $0.75 from $0.84 over nine months.
- Minor pointAcute graft-versus-host disease candidates showed activity at nanomolar concentrations, with preliminary results on drug handling and toxicity.
- Minor pointAgPlenus compounds showed activity against fungicide-resistant Septoria strains and additional fungal pathogens.
- Minor pointSeptoria disease severity fell by up to 75% versus untreated controls in plant tissue tests with selected compounds.
6 minor points
- Minor pointCost of revenues fell to $92,000 from $157,000 in Q3 and to $428,000 from $1.810 million over nine months.
- Minor pointNet research and development expense fell to $4.466 million from $4.635 million over nine months.
- Minor pointSales and marketing expense fell to $200,000 from $358,000 in Q3 and to $908,000 from $1.061 million over nine months.
- Minor pointNine-month general and administrative expense fell to $3.096 million from $3.154 million.
- Minor pointQuarterly net financing income rose to $176,000 from $79,000.
- Minor pointLavie Bio and Biomica operating expenses fell following the July 2025 ICL sale and the February 2026 Lishan licensing agreement.
Negative
- Major pointNet results swung to a $2.862 million Q3 loss from $5.197 million in income; the nine-month loss widened to $10.525 million from $2.473 million.
- Major pointRevenue fell to $141,000 from $312,000 in Q3 and to $822,000 from $3.189 million over nine months.
- Major pointOutstanding ordinary shares rose to 18,052,405 at September 30, 2026, from 8,718,193 at December 31, 2025.
- Moderate pointOperating loss widened to $2.982 million from $2.427 million in Q3 and to $8.369 million from $7.280 million over nine months.
- Moderate pointCash, cash equivalents and short-term bank deposits fell to approximately $9.2 million at September 30, 2026, from $12.956 million at December 31, 2025.
- Moderate pointQuarterly cash usage was approximately $2.4 million, including approximately $0.5 million for 18 months of directors’ and officers’ insurance. 7.9% of market cap
- Moderate pointEquity attributable to Evogene shareholders fell to negative $3.728 million at September 30, 2026, from negative $82,000 at year-end 2025.
- Moderate pointNine-month net financing results swung to $1.565 million in expense from $907,000 in income.
- Moderate pointQuarterly net research and development expense rose to $1.528 million from $1.133 million.
- Moderate pointWarrant transaction and non-recurring legal costs totaled approximately $0.3 million in Q3 and approximately $0.4 million over nine months. 6.3% of market cap
5 minor points
- Minor pointDiscontinued operations swung to a $56,000 Q3 loss from $7.561 million in income and to a $548,000 nine-month loss from $3.983 million in income.
- Minor point. Forward-looking: it has not happened yet and may not happen.Filing-enabling studies for the drug program remain ahead, and the drug handling and toxicology findings are preliminary.
- Minor pointGross profit fell to $49,000 from $155,000 in Q3 and to $394,000 from $1.379 million over nine months.
- Minor pointBayer’s license and collaboration agreement ended in May 2026, which Evogene cited as the main reason for lower quarterly revenue.
- Minor pointOther operating expenses were $191,000 in Q3 versus none a year earlier and $293,000 over nine months versus $191,000 in income.
News Explained
Evogene reported 18,052,405 ordinary shares outstanding at
Key Figures
- Cash, cash equivalents and short-term bank deposits
- approximately $9.2 million
- As of September 30, 2026
- Nine-month revenue
- approximately $0.8 million vs. approximately $3.2 million
- Nine months of 2026 vs. the same period of 2025
- Third-quarter revenue
- approximately $0.1 million vs. approximately $0.3 million
- Q3 2026 vs. Q3 2025
- Nine-month net loss
- approximately $10.5 million vs. approximately $2.5 million
- Nine months ended September 30, 2026 vs. 2025
- Third-quarter net result
- approximately $2.9 million net loss vs. $5.2 million net income
- Q3 2026 vs. Q3 2025
- Disease severity reduction
- up to 75%
- Selected fungicide compounds in plant tissue assays vs. untreated controls
Previous Earnings Reports
-
Revenue declined and net loss increased year over year; shares fell 3.24%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
agvhd medical
adme medical
ind-enabling studies regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria
REHOVOT,
Ofer Haviv, Evogene's President and CEO, stated: "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential. Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.
The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need. Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles. We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies. (For more information, please see our PR from 28, October 2026)
The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge. Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains. Selected compounds also reduced disease severity by up to
The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity. More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders. "
Financial Results and Analysis
Cash Position
As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately
Revenues
Revenues for the nine months of 2026 totaled approximately
Research and Development Expenses
Research and development expenses, net of non-refundable grants, for the nine months of 2026 were approximately
Sales and Marketing Expenses
Sales and marketing expenses for the nine months of 2026 were approximately
General and Administrative Expenses
General and administrative expenses for the nine months ended September 30, 2026, decreased slightly to approximately
Financing Expenses (Income), Net
Financing expenses, net, for the nine months of 2026 were approximately
Loss from Discontinued Operations
Loss from discontinued operations, net, for the nine months of 2026 was approximately
Net loss for the nine months ended September 30, 2026, was approximately
About Evogene Ltd.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
About AgPlenus Ltd.
AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs.
For more information, please visit www.agplenus.com
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its discovery program for new fungicides via AgPlenus; pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.
Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between
Investor Relations Contact:
ir@evogene.com
Tel: +972-8-9311901
|
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION |
||||
|
|
||||
|
|
||||
|
|
|
September 30, |
|
December 31, |
|
|
|
2026 |
|
2025 |
|
|
|
Unaudited |
|
|
|
ASSETS |
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
Cash and cash equivalents |
|
$ 8,571 |
|
$ 12,956 |
|
Restricted cash |
|
33 |
|
32 |
|
Short-term bank deposits |
|
655 |
|
- |
|
Trade receivables |
|
232 |
|
317 |
|
Other receivables and prepaid expenses |
|
1,181 |
|
1,565 |
|
Deferred expenses related to issuance of warrants |
|
- |
|
551 |
|
Inventories |
|
65 |
|
210 |
|
|
|
|
|
|
|
|
|
10,737 |
|
15,631 |
|
LONG-TERM ASSETS: |
|
|
|
|
|
Long-term deposits and other receivables |
|
5 |
|
571 |
|
Investment accounted for using the equity method |
|
- |
|
43 |
|
Deferred expenses related to issuance of warrants |
|
- |
|
1,165 |
|
Right-of-use-assets |
|
1,446 |
|
1,824 |
|
Property, plant and equipment, net |
|
446 |
|
812 |
|
|
|
|
|
|
|
|
|
1,897 |
|
4,415 |
|
|
|
|
|
|
|
TOTAL ASSETS |
|
$ 12,634 |
|
$ 20,046 |
|
|
|
|
|
|
|
LIABILITIES AND EQUITY |
|
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
Trade payables |
|
$ 593 |
|
$ 639 |
|
Employees and payroll accruals |
|
703 |
|
861 |
|
Lease liabilities |
|
618 |
|
716 |
|
Liabilities in respect of government grants |
|
142 |
|
56 |
|
Deferred revenues and other advances |
|
21 |
|
17 |
|
Warrants and pre-funded warrants liability |
|
496 |
|
706 |
|
Other payables |
|
389 |
|
449 |
|
|
|
|
|
|
|
|
|
2,962 |
|
3,444 |
|
LONG-TERM LIABILITIES: |
|
|
|
|
|
Lease liabilities |
|
1,287 |
|
1,482 |
|
Liabilities in respect of government grants |
|
3,082 |
|
3,073 |
|
Deferred revenues and other advances |
|
60 |
|
72 |
|
|
|
|
|
|
|
|
|
4,429 |
|
4,627 |
|
|
|
|
|
|
|
TOTAL LIABILITIES |
|
$ 7,391 |
|
$ 8,071 |
|
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION |
||||
|
|
||||
|
|
||||
|
|
||||
|
SHAREHOLDERS' EQUITY: |
|
|
|
|
|
Ordinary shares of Authorized − 30,000,000 ordinary shares; Issued and |
|
1,103 |
|
488 |
|
Share premium and other capital reserves |
|
288,212 |
|
281,986 |
|
Accumulated deficit |
|
(293,043) |
|
(282,556) |
|
|
|
|
|
|
|
Equity attributable to equity holders of the Company |
|
(3,728) |
|
(82) |
|
|
|
|
|
|
|
Non-controlling interests |
|
8,971 |
|
12,057 |
|
|
|
|
|
|
|
TOTAL EQUITY |
|
5,243 |
|
11,975 |
|
|
|
|
|
|
|
TOTAL LIABILITIES AND EQUITY |
|
$ 12,634 |
|
$ 20,046 |
|
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS |
||||||||||
|
|
||||||||||
|
|
||||||||||
|
|
|
Nine months ended September 30, |
|
Three months ended September 30, |
|
Year ended December 31, |
||||
|
|
|
2026 |
|
2025 (*) |
|
2026 |
|
2025 (*) |
|
2025 (*) |
|
|
|
Unaudited |
|
Audited |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ 822 |
|
$ 3,189 |
|
$ 141 |
|
$ 312 |
|
$ 3,503 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
Inventory impairment |
|
- |
|
- |
|
- |
|
- |
|
2,180 |
|
Other cost of revenues |
|
428 |
|
1,810 |
|
92 |
|
157 |
|
1,914 |
|
Total Cost of Revenues |
|
428 |
|
1,810 |
|
92 |
|
157 |
|
4,094 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
394 |
|
1,379 |
|
49 |
|
155 |
|
(591) |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development, net |
|
4,466 |
|
4,635 |
|
1,528 |
|
1,133 |
|
6,262 |
|
Sales and marketing |
|
908 |
|
1,061 |
|
200 |
|
358 |
|
1,359 |
|
General and administrative |
|
3,096 |
|
3,154 |
|
1,112 |
|
1,091 |
|
4,021 |
|
Other expenses (income) |
|
293 |
|
(191) |
|
191 |
|
- |
|
(205) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses, net |
|
8,763 |
|
8,659 |
|
3,031 |
|
2,582 |
|
11,437 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
(8,369) |
|
(7,280) |
|
(2,982) |
|
(2,427) |
|
(12,028) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing income |
|
2,559 |
|
2,352 |
|
255 |
|
513 |
|
2,618 |
|
Financing expenses |
|
(4,124) |
|
(1,445) |
|
(79) |
|
(434) |
|
(1,841) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing income (expenses), net |
|
(1,565) |
|
907 |
|
176 |
|
79 |
|
777 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Share of loss from equity accounted investment |
|
((43 |
|
(82) |
|
- |
|
(16) |
|
(39) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before taxes on income |
|
(9,977) |
|
(6,455) |
|
(2,806) |
|
(2,364) |
|
(11,290) |
|
Taxes on income (tax benefit) |
|
- |
|
1 |
|
- |
|
- |
|
1 |
|
Loss from continuing operations |
|
(9,977) |
|
(6,456) |
|
(2,806) |
|
(2,364) |
|
(11,291) |
|
Income (loss) from discontinued operations, net |
|
(548) |
|
3,983 |
|
(56) |
|
7,561 |
|
3,464 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ (10,525) |
|
$ (2,473) |
|
$ (2,862) |
|
$ 5,197 |
|
$ (7,827) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
|
|
|
|
|
|
Equity holders of the Company |
|
$ (10,487) |
|
$ (3,176) |
|
$ (2,849) |
|
$ 3,874 |
|
(8,485) |
|
Non-controlling interests |
|
(38) |
|
703 |
|
(13) |
|
1,323 |
|
658 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ (10,525) |
|
$ (2,473) |
|
$ (2,862) |
|
$ 5,197 |
|
$ (7,827) |
|
Basic and diluted loss per share from |
|
$ (0.75) |
|
$ (0.84) |
|
$ (0.17) |
|
$ (0.27) |
|
$ (1.41) |
|
Basic and diluted loss per share from |
|
$ (0.04) |
|
$ 0.42 |
|
$ (0.00) |
|
$ 0.71 |
|
$ 0.33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares used in |
|
13,245,869 |
|
7,588,486 |
|
16,894,446 |
|
8,716,424 |
|
7,874,039 |
|
|
||||||||||
|
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as |
||||||||||
|
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS |
|||||||||||
|
|
|||||||||||
|
|
|
Nine months ended September 30, |
|
Three months ended September 30, |
|
Year ended December 31, |
|||||
|
|
|
2026 |
|
2025 (*) |
|
2026 |
|
2025 (*) |
|
2025 (*) |
|
|
|
|
Unaudited |
|
Audited |
|||||||
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations |
|
$ (9,977) |
|
$ (6,456) |
|
$ (2,806) |
|
$ (2,364) |
|
$ (11,291) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to reconcile loss to net cash used in operating activities: |
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to the profit or loss items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation of property, plant and equipment and right-of-use-assets |
|
501 |
|
748 |
|
167 |
|
241 |
|
971 |
|
|
Impairment of Property, Plant and Equipment |
|
116 |
|
- |
|
- |
|
- |
|
- |
|
|
Inventory impairment |
|
- |
|
- |
|
- |
|
- |
|
2,180 |
|
|
Share-based compensation |
|
80) |
|
570 |
|
(13) |
|
125 |
|
728 |
|
|
Remeasurement of Convertible SAFE |
|
- |
|
(371) |
|
- |
|
(26) |
|
(371) |
|
|
Net financing expenses (income) |
|
(73) |
|
21 |
|
(81) |
|
(135) |
|
(28) |
|
|
Loss (gain) from sale of property, plant and equipment |
|
(17) |
|
(192) |
|
(3) |
|
2 |
|
(205) |
|
|
Revaluation of government grants |
|
27 |
|
24 |
|
18 |
|
24 |
|
40 |
|
|
Amortization of deferred expenses related to issuance of warrants |
|
1,716 |
|
989 |
|
- |
|
333 |
|
1,323 |
|
|
Remeasurement of pre-funded warrants and warrants |
|
(2,271) |
|
(1,664) |
|
(163) |
|
(346) |
|
(1,781) |
|
|
Expenses related to warrants inducement transaction |
|
2,095 |
|
- |
|
- |
|
- |
|
- |
|
|
Share of loss of an associate |
|
43 |
|
82 |
|
- |
|
15 |
|
39 |
|
|
Allowance for doubtful accounts |
|
78 |
|
- |
|
78 |
|
- |
|
- |
|
|
Investment in sub-lease |
|
194 |
|
- |
|
194 |
|
- |
|
- |
|
|
Taxes on income (tax benefit) |
|
- |
|
1 |
|
- |
|
- |
|
(6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,489 |
|
208 |
|
197 |
|
233 |
|
2,890 |
|
|
Changes in asset and liability items:
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease in trade receivables |
|
7 |
|
667 |
|
74 |
|
730 |
|
665 |
|
|
Decrease (increase) in other receivables and prepaid expenses |
|
(114) |
|
870 |
|
(388) |
|
(417) |
|
958 |
|
|
Decrease (increase) in inventories |
|
145 |
|
(740) |
|
28 |
|
(139) |
|
(1,019) |
|
|
Increase (decrease) in trade payables |
|
62 |
|
(195) |
|
187 |
|
(31) |
|
(40) |
|
|
Decrease in employees and payroll accruals |
|
(143) |
|
(335) |
|
(204) |
|
(226) |
|
(494) |
|
|
Increase (decrease) in other payables |
|
16 |
|
(343) |
|
117 |
|
(45) |
|
(344) |
|
|
Decrease in deferred revenues and other advances |
|
(8) |
|
(356) |
|
(5) |
|
(5) |
|
(361) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(35) |
|
(432) |
|
(191) |
|
(133) |
|
(635) |
|
|
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as |
|||||||||||
|
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS |
||||||||||
|
|
||||||||||
|
|
||||||||||
|
|
|
Nine months ended September 30, |
|
Three months ended September 30, |
|
Year ended December 31, |
||||
|
|
|
2026 |
|
2025 (*) |
|
2026 |
|
2025 (*) |
|
2025 (*) |
|
|
|
Unaudited |
|
Audited |
||||||
|
Cash received (paid) during the period for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest received |
|
246 |
|
221 |
|
46 |
|
45 |
|
338 |
|
Interest paid |
|
(104) |
|
(221) |
|
(20) |
|
(70) |
|
(256) |
|
Taxes paid |
|
(5) |
|
(11) |
|
- |
|
- |
|
(11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in continuing operating activities |
|
(7,386) |
|
(6,691) |
|
(2,774) |
|
(2,289) |
|
(8,965) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) discontinued operations activities |
|
(287) |
|
(4,125) |
|
13 |
|
(1,044) |
|
(4,537) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
$ (7,673) |
|
$ (10,816) |
|
$ (2,761) |
|
$ (3,333) |
|
$ (13,502) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment |
|
$ (13( |
|
(129) |
|
(2) |
|
(7) |
|
$ (199) |
|
Proceeds from sale of property, plant and equipment |
|
115 |
|
10 |
|
3 |
|
10 |
|
78 |
|
Proceeds from finance sub-lease asset |
|
17 |
|
29 |
|
- |
|
12 |
|
52 |
|
Investment in bank deposits, net |
|
(655) |
|
(3,700) |
|
(655) |
|
(2,699) |
|
(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) continuing investing activities |
|
(536) |
|
(3,790) |
|
(654) |
|
(2,684) |
|
(70) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) discontinued investing activities |
|
483 |
|
11,265 |
|
483 |
|
13,593 |
|
17,808 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities |
|
$ 53) ( |
|
$ 7,475 |
|
$ (171) |
|
$ 10,909 |
|
$ 17,738 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as |
||||||||||
|
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS |
|||||||||||
|
|
|||||||||||
|
|
|||||||||||
|
|
|
Nine months ended September 30, |
|
Three months ended September 30, |
|
Year ended December 31, |
|||||
|
|
|
2026 |
|
2025 (*) |
|
2026 |
|
2025 (*) |
|
2025 (*) |
|
|
|
|
Unaudited |
|
Audited |
|
||||||
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of ordinary shares, |
|
3,155 |
|
4,283 |
|
2,350 |
|
- |
|
4,283 |
|
|
Proceeds from issuance of ordinary shares |
|
3,206 |
|
- |
|
- |
|
- |
|
- |
|
|
Repayment of lease liability |
|
(334) |
|
(315) |
|
(121) |
|
(87) |
|
(423) |
|
|
Dividend paid by subsidiary |
|
(2,672) |
|
- |
|
- |
|
- |
|
- |
|
|
Repayment of convertible SAFE |
|
- |
|
(10,000) |
|
- |
|
(10,000) |
|
(10,000) |
|
|
Proceeds from government grants |
|
101 |
|
- |
|
- |
|
- |
|
- |
|
|
Repayment of government grants |
|
(34) |
|
(122) |
|
(14) |
|
- |
|
(244) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) continuing |
|
3,422 |
|
(6,154) |
|
2,215 |
|
(10,087) |
|
(6,384) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in discontinued financing |
|
(80) |
|
(192) |
|
(30) |
|
(249) |
|
(218) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing |
|
$ 3,342 |
|
$ (6,346) |
|
$ 2,185 |
|
$ (10,336) |
|
$ (6,602) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate differences - cash and cash |
|
(1) |
|
12 |
|
2 |
|
(13) |
|
21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease in cash and cash equivalents |
|
(4,385) |
|
(9,675) |
|
(745) |
|
(2,773) |
|
(2,345) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of the |
|
12,956 |
|
15,301 |
|
9,316 |
|
8,329 |
|
15,301 |
|
|
Cash and cash equivalents presented in |
|
- |
|
- |
|
- |
|
70 |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of the period |
|
$ 8,571 |
|
$ 5,626 |
|
$ 8,571 |
|
$ 5,626 |
|
$ 12,956 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant non-cash activities |
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of property, plant and |
|
$ - |
|
$ 2 |
|
$ - |
|
$ - |
|
$ 2 |
|
|
Right-of-use asset recognized with |
|
$ 33 |
|
$ 207 |
|
$- |
|
$ - |
|
$ 207 |
|
|
Exercise of pre-funded warrants |
|
$ - |
|
$ 389 |
|
$ - |
|
$ - |
|
$ 389 |
|
|
Derecognition of property, plant and |
|
$ - |
|
$ 13 |
|
$ - |
|
$ - |
|
13 $ |
|
|
|
|||||||||||
|
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as |
|||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-reports-financial-results-for-the-third-quarter-and-first-nine-months-of-2026-highlighting-progress-in-two-internal-development-programs-302945292.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.